188 related articles for article (PubMed ID: 29864718)
1. Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors.
Stucci LS; D'Oronzo S; Tucci M; Macerollo A; Ribero S; Spagnolo F; Marra E; Picasso V; Orgiano L; Marconcini R; De Rosa F; Di Guardo L; Galli G; Gandini S; Palmirotta R; Palmieri G; Queirolo P; Silvestris F;
Cancer Treat Rev; 2018 Sep; 69():21-28. PubMed ID: 29864718
[TBL] [Abstract][Full Text] [Related]
2. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
Hermel DJ; Ott PA
Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
Ouwerkerk W; van den Berg M; van der Niet S; Limpens J; Luiten RM
Melanoma Res; 2019 Oct; 29(5):453-464. PubMed ID: 30855527
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
Loo K; Daud AI
Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
[TBL] [Abstract][Full Text] [Related]
5. Immune check-point in cervical cancer.
De Felice F; Marchetti C; Palaia I; Ostuni R; Muzii L; Tombolini V; Benedetti Panici P
Crit Rev Oncol Hematol; 2018 Sep; 129():40-43. PubMed ID: 30097236
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis.
Grover S; Dougan M; Tyan K; Giobbie-Hurder A; Blum SM; Ishizuka J; Qazi T; Elias R; Vora KB; Ruan AB; Martin-Doyle W; Manos M; Eastman L; Davis M; Gargano M; Haq R; Buchbinder EI; Sullivan RJ; Ott PA; Hodi FS; Rahma OE
Cancer; 2020 Aug; 126(16):3758-3767. PubMed ID: 32567084
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy complements immune checkpoint blockade.
Ngiow SF; McArthur GA; Smyth MJ
Cancer Cell; 2015 Apr; 27(4):437-8. PubMed ID: 25873170
[TBL] [Abstract][Full Text] [Related]
8. Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences.
Buttigliero C; Allis S; Tucci M; Zichi C; Leone G; Di Stefano RF; Ruo Redda MG; Ricardi U; Scagliotti GV; Di Maio M; Filippi AR
Cancer Treat Rev; 2018 Sep; 69():215-223. PubMed ID: 30096699
[TBL] [Abstract][Full Text] [Related]
9. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors.
Zarbo A; Belum VR; Sibaud V; Oudard S; Postow MA; Hsieh JJ; Motzer RJ; Busam KJ; Lacouture ME
Br J Dermatol; 2017 Jun; 176(6):1649-1652. PubMed ID: 27943234
[TBL] [Abstract][Full Text] [Related]
10. Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy.
King GT; Sharma P; Davis SL; Jimeno A
Drugs Today (Barc); 2018 Feb; 54(2):103-122. PubMed ID: 29637937
[TBL] [Abstract][Full Text] [Related]
11. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
Spain L; Larkin J
Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
[No Abstract] [Full Text] [Related]
12. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
Camacho LH
Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA
Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy and immune checkpoint blockade: potential interactions and future directions.
Binder DC; Fu YX; Weichselbaum RR
Trends Mol Med; 2015 Aug; 21(8):463-5. PubMed ID: 26091823
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Komatsubara KM; Carvajal RD
Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18.
Ma Z; Li W; Yoshiya S; Xu Y; Hata M; El-Darawish Y; Markova T; Yamanishi K; Yamanishi H; Tahara H; Tanaka Y; Okamura H
Clin Cancer Res; 2016 Jun; 22(12):2969-80. PubMed ID: 26755531
[TBL] [Abstract][Full Text] [Related]
17. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
Simeone E; Ascierto PA
J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]